Research led by Public Health England found Pfizer’s vaccine was 88 percent effective against symptomatic infection from the variant two weeks after the second shot. For comparison, the shot is 93 percent effective against B.1.1.7, the dominant strain in the country.
AstraZeneca’s vaccine demonstrated 60 percent effectiveness against symptomatic disease from the variant in India, compared to 66 percent protection against the B.1.1.7 variant.
The study involved 1,054 people who were infected with the B.1.617.2 variant between April 5 and May 16.
Three weeks after one dose, the vaccines offered just 33 percent protection against symptomatic infection from the variant, underlining the importance of the two-dose schedule, experts said.
“We expect the vaccines to be even more effective at preventing hospitalization and death, so it is vital to get both doses to gain maximum protection against all existing and emerging variants,” said Dr. Mary Ramsay, head of immunization for the U.K.’s public health body.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
